[The role of mesenchymal stromal cells in solid organ transplantation]

Area of Science:

• Immunology
• Regenerative Medicine
• Transplantation Science

Background:

• Solid organ transplantation (SOT) is the primary treatment for end-stage organ failure.
• SOT outcomes are limited by immunological and non-immunological injuries affecting graft function and survival.
• Current research seeks novel strategies to mitigate SOT complications.

Purpose of the Study:

• To explore the potential of mesenchymal stromal cells (MSCs) in improving SOT.
• To investigate MSCs' capacity to attenuate ischemia/reperfusion injury.
• To assess MSCs' role in promoting graft repair and tolerance.

Main Methods:

• Review of preclinical studies and clinical trials on MSC administration in SOT.
• Analysis of MSC properties, including immunomodulation, anti-inflammation, and regeneration.
• Evaluation of MSC impact on ischemia/reperfusion damage and graft healing.

Main Results:

• Preclinical and clinical data suggest MSCs may offer benefits in SOT.
• MSCs possess demonstrated immunomodulatory, anti-inflammatory, and regenerative capabilities.
• These properties indicate potential for reducing transplant injury and improving outcomes.

Conclusions:

• Mesenchymal stromal cells represent a promising therapeutic approach for solid organ transplantation.
• MSC administration may mitigate key challenges in SOT, including injury and immune response.
• Further research and clinical application of MSCs could enhance long-term graft survival and patient outcomes.